A New Approach to Treating Gastroparesis
The Enterra System is the first and only device designed specifically to relieve the nausea and vomiting symptoms associated with gastroparesis from diabetes or unknown origins by gently stimulating your stomach – a unique kind of therapy called gastric electrical stimulation (GES).
Unlike other surgical treatment options, Enterra Therapy is implantable, customizable, and reversible.
How Enterra Therapy Works
A small neurostimulator that’s implanted under the skin
Two wires, called “leads”, that connect the neurostimulator to the stomach muscles
A handheld, external
programming device
Once it’s implanted, the neurostimulator sends mild electrical pulses through the leads to gently stimulate the smooth muscles of the lower stomach. These pulses are designed to relieve the chronic nausea and vomiting associated with gastroparesis.
Using the programming device, your doctor will adjust the neurostimulator to help ensure you receive the level of stimulation that’s right for you. Adjusting your Enterra system’s level of stimulation is non-invasive and does not require surgery.
How is Enterra Therapy implanted?
Implanting the Enterra System typically takes 1-2 hours under general anesthesia. Your doctor will choose one of two minimally invasive surgical techniques to implant the system, based on personal preference and medical needs:
- Robotic or Laparoscopic, in which special surgical instruments are inserted through small incisions.
Most people are able to go home within 1-2 days of the procedure, while some are even able to go home on the same day.
After the Procedure
After you receive your Enterra System, your doctor will use the external clinician programmer to customize the level of stimulation that’s right for you. Programming is non-invasive and can be done in your doctor’s office or the hospital. If you have another implanted device, your doctor will follow special programming considerations.
Is Enterra Therapy right for you?
Enterra Therapy is intended to reduce symptoms of chronic, drug-resistant nausea and vomiting associated with gastroparesis caused by diabetes or unknown causes in patients aged 18 to 70 years. But like any medical procedure, Enterra Therapy comes with risks, so it isn’t for everyone.
See if you’re a candidate to receive Enterra Therapy by taking the candidate screener.
Mary’s story
Hear from an Enterra Therapy Patient
“Enterra Therapy has given us hope – hope and the ability to fulfill the dreams that we wanted before I was diagnosed with gastroparesis”.
Mary is a mother of two and a grandmother of one who loves spending time outdoors with her family. However, unending nausea and vomiting from gastroparesis took over her life. Hear how Enterra Therapy helped give Mary and her family hope again.
Enterra Therapy FAQs
How large is the Enterra neurostimulator?
The Enterra II Neurostimulator model 37800 is 2.4 inches (60 mm) long, 2.2 inches (55 mm) high, and 0.5 inches (11.4 mm) thick. It weighs 1.6 ounces (45 grams).
Will the Enterra neurostimulator eliminate my nausea and vomiting symptoms?
Enterra Therapy has 5 randomized control trails completed over 20 years of clinical research. You should speak with your doctor regarding the clinical data for Enterra Therapy.
Among the patients that do experience relief, results vary. Often a combination of treatment options is necessary to maintain relief.
Can you feel the stimulation?
Most people report they do not feel the stimulation. Call your doctor if you notice any long-lasting pulsating, uncomfortable stimulation, or both, in your abdominal area.
Schedule a Consultation
Call (678) 626-0909 to request a consultation to see if Enterra Therapy is right for you. No referrals needed.
Important Safety Information
Enterra Therapy for chronic, resistant to medication nausea and vomiting associated with gastroparesis caused by diabetes or an unknown origin in patients aged 18 to 70 years: patients should always discuss potential risks and benefits of the device with their physician.
See full important safety information: https://www.enterramedical.com/important-safety-information
*Humanitarian Device
Authorized by federal law for use in the treatment of chronic intractable (drug refractory) nausea and vomiting secondary to gastroparesis of diabetic or idiopathic etiology in patients aged 18 to 70 years. The effectiveness of this device for this use has not been demonstrated.
1. Lacy BE, Crowell MD, Mathis C, Bauer D, Heinberg LJ.
Gastroparesis: Quality of Life and Health Care Utilization.
J Clin Gastroenterol.
2018;52(1):20‐24.doi:10.1097/MCG.0000000000000728.
2. Bielefeldt K, Raza N, Zickmund SL.
Bielefeldt K, Raza N, Zickmund SL.
Different faces of gastroparesis. World J Gastroenterol.
2009;15(48):6052‐6060. doi:10.3748/wjg.15.6052.
3. Wang YR, Fisher RS, Parkman HP.
Gastroparesis-related hospitalizations in the
United States: trends, characteristics, and outcomes, 1995-2004.
Am J Gastroenterol.
2008;103(2):313‐322. doi:10.1111/j.1572-0241.2007.01658.x.
4. Yu D, Ramsey FV, Norton WF, et al.
The Burdens, Concerns, and Quality of Life of Patients with Gastroparesis.
Dig Dis Sci. 2017;62(4):879‐893. doi:10.1007/s10620-017-4456-7.